Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

In 2016, cancer biologist Johanna Joyce of the Memorial Sloan Kettering Cancer Center published a study in Science that ...

Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as ...

Background Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer ...

A live webcast of the presentation will be available on the Events and Presentations section of Bicara’s website at www.bicara.com. An archived replay of the webcast will be available for ...

In 2024, the U.S. News & World Report chose the University of Texas MD Anderson Cancer Center in Houston, Texas, as the number one cancer hospital in the United States. This hospital is one of the ...

2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas. 3Department of Genomic Medicine, The University of Texas MD Anderson ...

according to the release. “Idiopathic pulmonary fibrosis is a devastating disease, and we look forward to working with TCGFB to discover antibodies targeting TGF-β as a potential novel ...

Five patients with uncontrolled lupus went into complete remission after undergoing a repurposed cancer treatment called CAR-T-cell therapy, which largely wiped out their rogue immune cells.

National’s Health spokesperson Dr Shane Reti says November 1 represents more transformative change for cancer patients under a Christopher Luxon-led Government, as 13 additional drugs funded from a ...